Get Access
TreelipClinical Program Risk Radar
Oncology Phase 2Methodology
NCT04032704

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Public trial-level signal summary for this oncology Phase 2 record.

Back to reportOpen ClinicalTrials.gov
Record overview

Status and phase

Status: TERMINATED

Phase: PHASE2

Sponsor: Seagen Inc.

Condition: Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma

Signal summary

Public flags

Status signal: Registry Stop Signal

Timeline signals: stale_update_signal

Results signal: Low Signal

Operational burden: large_enrollment_target_signal | rare_population_signal | strict_eligibility_signal

Stopped reason

Context when available

Study closed due to portfolio prioritization